Targeted therapy before surgery for HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You have HER2-positive breast cancer that has not spread to distant parts of the body
- You have not had any previous cancer treatment for this breast cancer (like chemotherapy, radiation, or targeted therapy)
- Your heart is working well (as shown by a normal heart ultrasound)
- Your liver, kidneys, and blood counts are in a healthy range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for HER2-positive breast cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.